Product Images Aripiprazole

This is a medication description for orally disintegrating tablets of Aripiprazole. It provides information on dosage, storage, and handling of the medication. However, some parts of the text are incomplete or illegible, making it difficult to understand its entirety.*

This text describes the effect of different drugs on the PK (pharmacokinetics) of Aripiprazole, a type of medication used to treat mental/mood disorders. The drugs are classified based on their inhibition/induction of specific enzymes (CYP3A4 or CYP2DE) involved in the metabolism of Aripiprazole. The text presents fold change and 90% CI (confidence interval) data for Aripiprazole levels after co-administration with each drug. The drugs include CYP3A4 inhibitors such as ketoconazole, CYP2DE inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers like famotidine, and others like Viproste and forazepam.*

This text appears to be a table showing the effect of different drugs on Aripiprazole, indicating which drugs inhibit or induce certain enzymes that affect the metabolism of the drug. It also shows the fold change and confidence interval of Dehydro-Aripiprazole, a metabolite of Aripiprazole, when interacting with these drugs. However, the table is not readable without the associated figures and legends.*

This text appears to be a medical or pharmacological study that analyses the effect of Aripiprazole on other drugs by measuring the concentration of various drugs in the blood after administration of Aripiprazole. The study seems to mention various drugs including dextromethorphan, warfarin, omeprazole, venlafaxine, lithium and lorazepam and the change in their concentration after administration of Aripiprazole. However, due to lack of context and complete sentences, more details cannot be provided.*

This appears to be a table displaying information related to the effects of factors such as genetics (CYP2D6 metabolizer status), gender, age, and liver/kidney function on the pharmacokinetics (PK) of Aripiprazole. The table shows measurements of drug exposure (AUC) and peak concentration (Cmax) for the various populations studied. There is also information related to the statistical significance of changes observed in drug PK compared to a reference group.*

This text appears to be a graph showing the proportion of subjects with relapse over time for two different groups: one group taking a medication called Aripiprazole and the other group taking a placebo. The number of subjects at risk is shown for both groups at various time points. Not available for further interpretation without more context.*

This appears to be a graph depicting the proportion of subjects with relapse over a certain number of days from randomization, with one group receiving aripiprazole and the other group receiving a placebo. The x-axis shows the number of days from randomization and the y-axis shows the proportion of subjects with relapse. The number of subjects at risk is also shown for each group at different time points.*

Each orally disintegrating tablet contains 15 g of aripiprazole, USP, and is intended for use as indicated in the package insert. This medication should be stored in tightly closed containers between 15°C to 30°C (59°F to 86°F). Patients with phenylketonuria should be aware that each 15 mg orally disintegrating tablet contains 1.68 mg of phenylalanine. The medication guide should be provided to each patient by the dispensing pharmacist. Keep this and all medication out of the reach of children. The lot number is not readable.*